Pharmaceutical

Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?

MK-0616 is a peptide commercialized by Merck, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH).

Sep 19, 2023 - 20:00
Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?
MK-0616 is a peptide commercialized by Merck, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Kroger Health Joins Hands With Performance Kitchen to Provide Medically Tailored...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Federal group studying surprise ambulance bills will finally meet — four months late

STAT+: Federal group studying surprise ambulance bills ...

Apr 13, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Sanofi’s frexalimab shows early potential in in Phase I...

Jun 1, 2023

STAT+: In Silicon Valley, a venture capital firm gives health tech startups a crash course in getting paid

STAT+: In Silicon Valley, a venture capital firm gives ...

May 15, 2023